RxDoctor Payments Data

Michael D'urso, MD

Cardiovascular Disease · Rapid City, SDNPI 1699720631

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Abbott at 41.8% of the total. Reporting peaked in 2021 at $91 and has fallen 63.1% since, to $34 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in SD, where the typical reported total is $1,542.

$217in general payments, 2019–2025

Across 14 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$91
  • Chiesi USA, Inc.$51
  • Boston Scientific$37
  • Johnson & Johnson$14
  • Amgen$12
  • AstraZeneca$11
$46,325in research payments, 2019–2025

Across 1 payment — averaging $46,325 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$46K

What the payments were for

  • Food & beverage$20594%
  • Education$126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$217 in reported general payments places this provider in the 20th percentile of 33 cardiovascular disease providers in South Dakota.

See all cardiovascular disease providers in South Dakota

Medicare billing

Part B allowed, 2024
$164,489
Medicare patients
2,009
Services billed
3,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$190,750
Repatha SureclickEvolocumab77$96,475
XareltoRivaroxaban40$56,689
EntrestoSacubitril/Valsartan26$43,639
Praluent PenAlirocumab19$25,143
VascepaIcosapent Ethyl17$8,327
Metoprolol Succinate325$5,874
Atorvastatin Calcium334$3,530
Prasugrel Hcl28$3,156
Ezetimibe133$2,764
Potassium Chloride103$1,996
Warfarin Sodium192$1,875
Icosapent Ethyl11$1,772
Losartan Potassium196$1,768
Rosuvastatin Calcium143$1,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$14$56,68940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 33 cardiovascular disease providers in South Dakota.

Other cardiovascular disease in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →